Search the Newsreel

Q4 2025 Personalis Inc Earnings Call Transcript

Personalis Inc. (PSNL) achieved significant clinical growth in Q4 2025, with a 329% year-over-year increase in clinical tests delivered and secured two Medicare coverage decisions for breast and lung cancer, validating their MRD technology. Despite a planned decline in legacy contract revenue and compressed …

Calisa Acquisition (NASDAQ: ALIS) backs 100 MW GoodVision AI factory plan in Japan

Calisa Acquisition Corp. (NASDAQ: ALIS) announced support for its proposed business combination partner, GoodVision AI, in its plan to develop a 100 MW AI Factory network in Japan through a strategic cooperation with AI Storm Co., Ltd. The initiative will begin with a 2 …

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

Zentalis Pharmaceuticals announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026, highlighting overall survival data for azenosertib in platinum-resistant ovarian cancer from the DENALI Part 1b study with a rapid oral presentation. The company will also present a trial-in-progress poster …

Personalis draws takeover interest from Merck (PSNL:NASDAQ)

Personalis (PSNL) shares surged in premarket trading after reports indicated the company is exploring a potential sale. Merck (MRK) and two other bidders have reportedly expressed takeover interest in the cancer test maker. This news suggests a significant acquisition opportunity in the biotech sector.

Personalis moves off low after blog claims company exploring possible sale

Personalis (PSNL) saw its stock move off its low after a blog claimed the company is exploring a possible sale. This news follows recent analyst price target increases and expanded coverage for their NeXT Personal test, including UKCA marking, EU CE-IVD mark, and Medicare …

Zentalis Pharmaceuticals Announces ESMO 2026 Rapid Oral Presentation of DENALI Overall Survival Data for Azenosertib in Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals announced that overall survival data from its DENALI Part 1b study of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer will be presented as a rapid oral presentation at the ESMO Congress 2026. This presentation highlights the potential for long-term survival benefits, supporting …

New Talisman Gold Mines Limited Ordinary Shares (NZX:NTL)

Mizuho Initiates Zentalis Pharmaceuticals at Outperform With $8 Price Target

Mizuho initiated coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with an Outperform rating and set an $8 price target. The firm highlighted Zentalis' strategic shift to focus on its WEE1 inhibitor, ZN-c3, in ovarian cancer. Mizuho believes that positive data from the Phase 3 ZN-c3 …

Why Is PSNL Stock Up 5% After-Hours?

Shares of Personalis (PSNL) rose 5% after-hours following rumors that the precision oncology company is exploring strategic options, including a potential sale, due to takeover interest from Merck & Co. (MRK) and other parties. Personalis has hired investment banks and a law firm to …

Personalis attracting takeover interest, Street Insider says

Personalis (PSNL), a precision oncology company, is reportedly attracting takeover interest from Merck (MRK) and at least two other suitors. The company has hired bankers from Centerview and TD Securities, along with legal counsel from Cooley, to evaluate a potential sale. This information comes …

Materialise (MTLS) Projected to Post Earnings on Thursday

Materialise (NASDAQ: MTLS) is expected to report its earnings before the market opens on Thursday, July 23rd, with analysts forecasting EPS of $0.0457 on revenue of $78.23 million. The company's stock currently holds a consensus "Hold" rating from analysts with a price target of …

Borealis Foods launches high-protein Chef Woo noodles at Costco amid rising demand for nutritious meals.

Borealis Foods has introduced its Chef Woo High-Protein Noodles at Costco, with strong initial demand attributed to consumer interest in convenient, protein-rich foods, partly influenced by GLP-1 weight loss medications. Each serving provides 20 grams of complete protein, meeting the rising preference for healthier …

Form 4 Personalis Inc For: 15 July By Investing.com

This article announced a Form 4 filing for Personalis Inc. (PSNL) on July 15th, 2026, noting that the stock was up 5.06% at the time of publication. The brief piece serves as a notice of the regulatory filing.

[144] Personalis, Inc. SEC Filing

This article details a Form 144 SEC filing by Personalis, Inc. (PSNL), indicating a proposed sale of 100,000 shares of common stock with an aggregate market value of $1,503,000. The shares were acquired through the exercise of stock options on July 15, 2026, and …

Personalis president and CMO Richard Chen sells $1.5m in stock

Richard Chen, President and Chief Medical Officer of Personalis, Inc., sold 100,000 shares of company stock for $1.515 million after exercising options. The transaction was executed under a Rule 10b5-1 trading plan. The sale occurred as PSNL trades near its 52-week high, though InvestingPro …

Materialise Updates Share Buyback Progress, Now Holding 1.9% of Its Shares in Treasury

Materialise NV has provided an update on its share buyback program, reporting that it repurchased 26,064 shares between July 6 and July 10, 2026. Since the program's start in January 2026, the company has bought back 1,106,406 shares, totaling approximately 1.9% of its outstanding …

Tialis Essential IT Names Zeus Capital as New Nominated Adviser and Broker Effective Immediately

PSNL Forecast — Price Target — Prediction for 2027

PALI Forecast — Price Target — Prediction for 2027

Personalis Inc. (PSNL) Q1 2026 Earnings: Wider-than-Expected Loss but Stock Surges Over 10% - Tech Earnings Analysis

MDRR Q2 2021 Earnings: Better-than-Expected EPS Marks Improvement - EPS Revision Trend

Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating (NASDAQ:PSNL)

Talisman Mining (ASX:TLM) Gains Attention After CEO Transition Update

PSNL - Personalis Inc Stock Price and Quote

We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn

Chemfab Alkalis FY26 Net Profit Rs 750.59 Lakh; Dividend Rs 1.25 Per Share

AtkinsRéalis Group Inc. 2026 Q1 - Results - Earnings Call Presentation (TSX:ATRL:CA) 2026-05-14

ATRL: Q1 saw double-digit revenue and earnings growth, robust backlog, and a positive 2026 outlook

Chemfab Alkalis Posts ₹5M Q4 Profit Swinging from ₹92M Loss as Revenue Dips 19%

Medalist Diversified, Inc. 1Q 2026: Revenue $2.16M, Net income $8.97M, EPS $4.85— 10-Q Summary

Personalis Q1 Earnings Call Highlights

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

Medalist’s first DST deal centers on a Tesla sales and service site

ERSAN ALISVERIS - KAP Haberleri - 2026-04-18 tarihli

ASX Movers: Talisman Mining (ASX:TLM) Falls 13% Amid Resources Sector Pressure

Personalis Stock Pre-Market (-5.3%): FY26 Guidance Overshadows Q4 EPS Beat